Celonis is a process mining and execution management company that is increasingly positioning its platform as critical infrastructure for enterprise artificial intelligence initiatives, and this weekly recap summarizes notable developments from the past week. The company continued to emphasize its role as the operational context layer for AI, enabling models to understand how businesses run, where processes break down, and how to optimize end-to-end workflows.
A key highlight was Novo Nordisk’s use of Celonis technology to build a “digital twin” of its clinical development operations, described as a “digital brain” that provides the context needed to deploy and monitor more than 100 AI agents across drug development workflows. Novo Nordisk aims to cut up to two years from the typical 12-year drug development timeline by identifying bottlenecks such as stalled handoffs and idle data.
This use case underscores Celonis’s potential to improve R&D efficiency in highly regulated industries and positions its platform as core infrastructure for AI orchestration in complex environments. The ability to pinpoint whether performance issues stem from specific AI agents or underlying processes may make Celonis more integral to enterprise AI strategies and support deeper, stickier customer engagements.
In parallel, Celonis continued to spotlight a strategic engagement with NEC Corporation, which the company describes as pursuing an “AI-native” strategy and engaging with Celonis at its Executive Briefing Centers in Munich and New York. This signals growing interest from large global enterprises in using Celonis to operationalize AI at scale and enhance process efficiency across their operations.
Celonis also ramped promotion of its upcoming Celosphere 26 event, focusing on themes of artificial intelligence and value generation for customers and partners. The company highlighted opportunities for attendees to learn how to realize value quickly with AI, hear from high-profile speakers, and connect with experts and peers, while offering limited-time pricing incentives such as a €650 discount for the first 300 sign-ups.
The company indicated that Celosphere 26 will showcase what it characterizes as major advances for the Celonis Platform and feature “changemakers” associated with more than $10 billion in realized value. If Celonis can demonstrate tangible returns from AI-enabled process optimization and deliver meaningful platform enhancements, these developments could strengthen its competitive position and support long-term demand, marking a strategically constructive week for the company.


